6953-61-3
基本信息
Naphthohydroxamicacid
a-Naphthohydroxamic acid
1-NAPHTHOHYDROXAMIC ACID
alpha-naphthohydroxamicacid
1-NAPHTHOHYDROXAMIC ACID 98+%
HDAC Inhibitor XIX, Compound 2
1-Naphthalenecarbohydroximic acid
n-hydroxy-1-naphthalenecarboxamid
N-Hydroxy-1-naphthalenecarboxamide
物理化学性质
储存条件 | 2-8°C |
溶解度 | 二甲基亚砜:≥5mg/mL |
形态 | 白色固体 |
颜色 | 白色至棕褐色 |
安全数据
危险性符号(GHS) | GHS07 |
警示词 | 警告 |
危险性描述 | H312-H302-H332 |
防范说明 | P280-P302+P352-P312-P322-P363-P501-P264-P270-P301+P312-P330-P501-P261-P271-P304+P340-P312 |
危险类别码 | 52 |
WGK Germany | 3 |
RTECS号 | QJ1894500 |
海关编码 | 2928009090 |
图谱信息
1-萘羟肟酸(6953-61-3)质谱(MS)1-萘羟肟酸(6953-61-3)核磁图(1HNMR)1-萘羟肟酸(6953-61-3)核磁图(13CNMR)1-萘羟肟酸(6953-61-3)红外图谱(IR1)1-萘羟肟酸价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2024/11/08 | HY-130538 | 1-萘羟肟酸 1-Naphthohydroxamic acid | 6953-61-3 | 5mg | 650元 |
2024/11/08 | HY-130538 | 1-萘羟肟酸 1-Naphthohydroxamic acid | 6953-61-3 | 10mM * 1mLin DMSO | 720元 |
2024/11/08 | HY-130538 | 1-萘羟肟酸 1-Naphthohydroxamic acid | 6953-61-3 | 10mg | 1200元 |
常见问题列表
HDAC8 14 μM (IC 50 ) |
HDAC1 >100 μM (IC 50 ) |
HDAC6 >100 μM (IC 50 ) |
1-Naphthohydroxamic acid (compound 2; 20-40 µM; 0-144 hours; BE(2)-C, SK-N-BE(2) and SH-SY5Y cells) treatment reduces cell numbers in a concentration-dependent manner.
1-Naphthohydroxamic acid (compound 2) at concentrations in the range of its in vitro IC
50
against HDAC8 results in reduced cell density and outgrowth of neurite-like structures that stained positive for neurofilament.1-Naphthohydroxamic acid reduces the formation of clones in soft-agar concentration dependently.
When either cell type (HeLa and HEK293 cells) is treated with 1-Naphthohydroxamic acid (compound 2; 0.8 µM, 4 µM, 20 µM or 100 µM), only tubulin becomes hyperacetylated.
Cell Proliferation Assay
Cell Line: | BE(2)-C, SK-N-BE(2) and SH-SY5Y cells |
Concentration: | 20 µM, 40 µM |
Incubation Time: | 0 hours, 24 hours, 48 hours, 72 hours, 96 hours, and 144 hours |
Result: | Reduced cell numbers in a concentration-dependent manner. |
Dose-limiting toxicities (DLTs) of 1-Naphthohydroxamic acid (compound 2; 0-40 mg/kg; intraperitoneal injection; daily; for 10 day; NMRI
Foxn1
nude mice) include weight loss and signs of liver toxicity, as evidenced by elevated plasma liver enzymes and detection of necrotic areas on histological liver examination. 1-Naphthohydroxamic acid has the maximum tolerable doses at 50 mg/kg per day. At these concentrations, neither body weight nor blood parameters are critically changed.
Pharmacokinetic studies after intraperitoneal administration of the inhibitors identified the half-life of 1-Naphthohydroxamic acid to be ~15 min, with a plasma peak concentration of ~30 μM.
Animal Model: | NMRI Foxn1 nude mice |
Dosage: | 0 mg/kg, 50 mg/kg, 100mg/kg, 200 mg/kg, 300 mg/kg 400 mg/kg |
Administration: | Intraperitoneal injection; daily; for 10 days |
Result: | Dose-limiting toxicities (DLTs) included weight loss and signs of liver toxicity, as evidenced by elevated plasma liver enzymes and detection of necrotic areas on histological liver examination. |